Altimmune Announces Positive Results from NasoVAX Extension Study

Altimmune (NASDAQ:ALT) has announced positive data from its Phase 2 extension study of NasoVAX intranasal influenza vaccine candidate.

As quoted in the press release:

Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination.

Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination. Of 15 subjects invited, 8 returned an average of 13.5 months after vaccination. Antibody titers for all 8 subjects remained seroprotective, with a median hemagglutination inhibition (HAI) titer more than 3-times higher than generally accepted seroprotective levels. Coupled with previously demonstrated mucosal antibody and T-cell related correlates of immunoprotection, NasoVAX is well positioned to compete with other influenza vaccines currently under development.

“We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market,” said Vipin K. Garg, Ph.D., President and CEO of Altimmune. “Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets. We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases. The proceeds from our recent successful financing efforts have put us in a strong position to execute our acquisition plans.”

Click here to read the full press release.